fluoxetine has been researched along with Psychoses in 38 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A case of acute myocarditis associated with the commencement of clozapine is described, highlighting the onset, course and possible contributing factors." | 7.74 | Acute myocarditis associated with clozapine. ( Howpage, P; Varambally, S, 2007) |
| "The authors present a case report of neuroleptic malignant syndrome (NMS) in a patient commencing treatment with fluoxetine alone who had previously been treated with several antipsychotic and antidepressant combinations." | 7.68 | Fluoxetine and neuroleptic malignant syndrome. ( Goldbloom, DS; Halman, M, 1990) |
| "Case 2 was a female with schizoaffective disorder without a history of NMS." | 6.52 | Atypical neuroleptic malignant syndrome in patients treated with aripiprazole and clozapine: a case-series study and short review. ( Chang, CH; Chang, YC; Chen, YW; Cheng, YS; Chung, W; Tseng, PT; Wang, HY; Wu, CK, 2015) |
| "Fluoxetine is a relatively new antidepressant, reported to have minimal side-effects." | 6.38 | Seizures associated with fluoxetine therapy. ( Prasher, VP, 1993) |
| "In this sample of children and adolescents with epilepsy and depressive disorders, we observed that SSRIs are a good therapeutic option, considering their efficacy in remission of depressive symptoms, their few adverse effects, and their maintenance of satisfactory seizure control." | 5.34 | Sertraline and fluoxetine: safe treatments for children and adolescents with epilepsy and depression. ( Kuczynski, E; Thomé-Souza, MS; Valente, KD, 2007) |
| "The effects of fluoxetine and imipramine on the pharmacokinetics and nonpsychiatric side effect profile of quetiapine fumarate were investigated in 26 patients with schizophrenia, schizoaffective disorder, or bipolar disorder in a multicenter, two-period, multiple-dose, open-label, randomized trial." | 5.10 | Effect of fluoxetine and imipramine on the pharmacokinetics and tolerability of the antipsychotic quetiapine. ( Alva, G; Arvanitis, LA; Carreon, D; Kalali, A; Potkin, SG; Thyrum, PT; Yeh, C, 2002) |
| "A case of acute myocarditis associated with the commencement of clozapine is described, highlighting the onset, course and possible contributing factors." | 3.74 | Acute myocarditis associated with clozapine. ( Howpage, P; Varambally, S, 2007) |
| "The authors present a case report of neuroleptic malignant syndrome (NMS) in a patient commencing treatment with fluoxetine alone who had previously been treated with several antipsychotic and antidepressant combinations." | 3.68 | Fluoxetine and neuroleptic malignant syndrome. ( Goldbloom, DS; Halman, M, 1990) |
| "The Staged Treatment in Early Psychosis (STEP) sequential multiple assignment randomized trial took place within the clinical program at Orygen, Melbourne, Australia." | 3.30 | A Sequential Adaptive Intervention Strategy Targeting Remission and Functional Recovery in Young People at Ultrahigh Risk of Psychosis: The Staged Treatment in Early Psychosis (STEP) Sequential Multiple Assignment Randomized Trial. ( Amminger, GP; Baird, S; Buccilli, K; Carter, C; Dempsey, SA; Dixon, L; Ferguson, N; Formica, M; Kerr, M; Krcmar, M; Loewy, R; McGorry, PD; Mebrahtu, Y; Mei, C; Nelson, B; Niendam, TA; Polari, A; Quinn, AL; Ruslins, A; Shumway, M; Spark, J; Street, R; Wallis, N; Wannan, C; Yuen, HP, 2023) |
| " The severity and incidence of extrapyramidal symptoms and adverse events did not significantly increase when fluoxetine was added." | 2.70 | The effect of fluoxetine on the pharmacokinetics and safety of risperidone in psychotic patients. ( Baumann, P; Bertschy, G; Bondolfi, G; Eap, CB; Vermeulen, A; Zullino, D, 2002) |
| "With valproic acid, there was a minor increase in total clozapine metabolites, which was even less with dose correction." | 2.67 | Serum concentrations of clozapine and its major metabolites: effects of cotreatment with fluoxetine or valproate. ( Baldessarini, RJ; Centorrino, F; Flood, JG; Frankenburg, FR; Kando, J; Puopolo, PR; Volpicelli, SA, 1994) |
| "Case 2 was a female with schizoaffective disorder without a history of NMS." | 2.52 | Atypical neuroleptic malignant syndrome in patients treated with aripiprazole and clozapine: a case-series study and short review. ( Chang, CH; Chang, YC; Chen, YW; Cheng, YS; Chung, W; Tseng, PT; Wang, HY; Wu, CK, 2015) |
| "Fluoxetine is a relatively new antidepressant, reported to have minimal side-effects." | 2.38 | Seizures associated with fluoxetine therapy. ( Prasher, VP, 1993) |
| "In this sample of children and adolescents with epilepsy and depressive disorders, we observed that SSRIs are a good therapeutic option, considering their efficacy in remission of depressive symptoms, their few adverse effects, and their maintenance of satisfactory seizure control." | 1.34 | Sertraline and fluoxetine: safe treatments for children and adolescents with epilepsy and depression. ( Kuczynski, E; Thomé-Souza, MS; Valente, KD, 2007) |
| "Data from an intensive observational drug utilization study were analyzed to determine whether patients who received the combination of fluoxetine and lithium had more and different adverse events as compared with those receiving fluoxetine alone." | 1.29 | Adverse events and tolerability of the combination of fluoxetine/lithium compared with fluoxetine. ( Bauer, M; Linden, M; Schaaf, B; Weber, HJ, 1996) |
| "Fluoxetine (20 mg/day) was added for 7-10 days to stable doses of haloperidol given to eight psychotic patients." | 1.28 | Elevation of plasma concentrations of haloperidol after the addition of fluoxetine. ( Baldessarini, RJ; Brotman, AW; Goff, DC; Midha, KK; Waites, M, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 18 (47.37) | 18.2507 |
| 2000's | 13 (34.21) | 29.6817 |
| 2010's | 6 (15.79) | 24.3611 |
| 2020's | 1 (2.63) | 2.80 |
| Authors | Studies |
|---|---|
| McGorry, PD | 1 |
| Mei, C | 1 |
| Amminger, GP | 1 |
| Yuen, HP | 1 |
| Kerr, M | 1 |
| Spark, J | 1 |
| Wallis, N | 1 |
| Polari, A | 1 |
| Baird, S | 1 |
| Buccilli, K | 1 |
| Dempsey, SA | 1 |
| Ferguson, N | 1 |
| Formica, M | 1 |
| Krcmar, M | 1 |
| Quinn, AL | 1 |
| Mebrahtu, Y | 1 |
| Ruslins, A | 1 |
| Street, R | 1 |
| Wannan, C | 1 |
| Dixon, L | 1 |
| Carter, C | 1 |
| Loewy, R | 1 |
| Niendam, TA | 1 |
| Shumway, M | 1 |
| Nelson, B | 1 |
| Zubair, UB | 1 |
| Mansoor, S | 1 |
| Tseng, PT | 1 |
| Chang, YC | 1 |
| Chang, CH | 1 |
| Wang, HY | 1 |
| Cheng, YS | 1 |
| Wu, CK | 1 |
| Chen, YW | 1 |
| Chung, W | 1 |
| Rao, SA | 1 |
| Rao, MG | 1 |
| Rao, NP | 1 |
| Varambally, S | 2 |
| Gangadhar, BN | 1 |
| Dording, CM | 2 |
| Sinicropi-Yao, L | 1 |
| Papakostas, G | 1 |
| Matthews, JD | 2 |
| Nierenberg, AA | 1 |
| Fava, M | 2 |
| Mischoulon, D | 2 |
| Neckelmann, D | 1 |
| Maehlum, E | 1 |
| Waage, IM | 1 |
| Houston, J | 1 |
| Dharia, S | 1 |
| Bishop, JR | 1 |
| Ellingrod, VL | 1 |
| Fijal, B | 1 |
| Jacobson, JG | 1 |
| Hoffmann, VP | 1 |
| Saddichha, S | 1 |
| Kumar, R | 1 |
| Babu, GN | 1 |
| Chandra, P | 1 |
| Bottonari, KA | 1 |
| Polania, LM | 1 |
| Irvin, R | 1 |
| Dai, ZY | 1 |
| Jiang, SS | 1 |
| Jaffe, R | 1 |
| Leavitt, R | 1 |
| Wind, T | 1 |
| Rothschild, AJ | 1 |
| Williamson, DJ | 1 |
| Tohen, MF | 1 |
| Schatzberg, A | 1 |
| Andersen, SW | 1 |
| Van Campen, LE | 1 |
| Sanger, TM | 1 |
| Tollefson, GD | 1 |
| Thomé-Souza, MS | 1 |
| Kuczynski, E | 1 |
| Valente, KD | 1 |
| Howpage, P | 1 |
| Wolf, J | 1 |
| Salo, R | 1 |
| Kulik, FA | 1 |
| Wilbur, R | 1 |
| Stoll, AL | 1 |
| Mayer, PV | 1 |
| Kolbrener, M | 1 |
| Goldstein, E | 1 |
| Suplit, B | 1 |
| Lucier, J | 1 |
| Cohen, BM | 1 |
| Tohen, M | 1 |
| Prasher, VP | 1 |
| Centorrino, F | 1 |
| Baldessarini, RJ | 2 |
| Kando, J | 1 |
| Frankenburg, FR | 1 |
| Volpicelli, SA | 1 |
| Puopolo, PR | 1 |
| Flood, JG | 1 |
| Ninan, PT | 1 |
| Shelton, S | 1 |
| Sichel, DA | 1 |
| Cohen, LS | 1 |
| Dimmock, JA | 1 |
| Rosenbaum, JF | 1 |
| Bauer, M | 1 |
| Linden, M | 1 |
| Schaaf, B | 1 |
| Weber, HJ | 1 |
| Arya, DK | 1 |
| Taylor, WS | 1 |
| Bach, M | 1 |
| Aigner, M | 1 |
| Lenz, G | 1 |
| Benazzi, F | 1 |
| Eap, CB | 2 |
| Bondolfi, G | 2 |
| Zullino, D | 2 |
| Savary-Cosendai, L | 1 |
| Powell-Golay, K | 1 |
| Kosel, M | 1 |
| Baumann, P | 2 |
| Padla, D | 1 |
| Rodgers, TA | 1 |
| Potkin, SG | 1 |
| Thyrum, PT | 1 |
| Alva, G | 1 |
| Carreon, D | 1 |
| Yeh, C | 1 |
| Kalali, A | 1 |
| Arvanitis, LA | 1 |
| Bertschy, G | 1 |
| Vermeulen, A | 1 |
| Bacher, NM | 1 |
| Ruskin, P | 1 |
| Altman, S | 1 |
| Stein, B | 1 |
| Fernandez, F | 1 |
| Levy, JK | 1 |
| Gernaat, HB | 1 |
| Van de Woude, J | 1 |
| Touw, DJ | 1 |
| Deckert, DW | 1 |
| Malone, DA | 1 |
| Goff, DC | 1 |
| Midha, KK | 1 |
| Brotman, AW | 1 |
| Waites, M | 1 |
| Komoroski, RA | 1 |
| Newton, JE | 1 |
| Karson, C | 1 |
| Cardwell, D | 1 |
| Sprigg, J | 1 |
| Halman, M | 1 |
| Goldbloom, DS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy and Safety of Olanzapine in Patients With Borderline Personality Disorder: A Randomized Double-Blind Comparison With Placebo[NCT00088036] | Phase 3 | 450 participants | Interventional | 2004-02-29 | Completed | ||
| Olanzapine Versus Divalproex and Placebo in the Treatment of Mild to Moderate Mania Associated With Bipolar I Disorder[NCT00094549] | Phase 4 | 500 participants | Interventional | 2004-10-31 | Completed | ||
| The Study of Olanzapine Plus Fluoxetine in Combination for Treatment-Resistant Depression Without Psychotic Features[NCT00035321] | Phase 3 | 600 participants | Interventional | 2002-04-30 | Completed | ||
| Efficacy and Safety of Olanzapine in Patients With Borderline Personality Disorder: A Randomized Flexible Dose Double-Blind Comparison With Placebo[NCT00091650] | Phase 3 | 300 participants | Interventional | 2004-03-31 | Completed | ||
| Olanzapine/Fluoxetine Combination Versus Lamotrigine in the Treatment of Bipolar I Depression[NCT00485771] | Phase 4 | 403 participants (Actual) | Interventional | 2003-11-30 | Completed | ||
| Sequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD) a Multicentre Open-label Randomized Controlled Trial Protocol[NCT05814640] | Phase 1/Phase 2 | 520 participants (Anticipated) | Interventional | 2023-02-20 | Recruiting | ||
| Quetiapine in the Treatment of Psychotic Depression - a Pilot Study[NCT00751504] | Phase 3 | 16 participants (Actual) | Interventional | 2008-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for fluoxetine and Psychoses
| Article | Year |
|---|---|
Atypical neuroleptic malignant syndrome in patients treated with aripiprazole and clozapine: a case-series study and short review.
Topics: Adult; Aripiprazole; Clozapine; Creatine Kinase; Dose-Response Relationship, Drug; Drug Substitution | 2015 |
Seizures associated with fluoxetine therapy.
Topics: Adult; Depressive Disorder; Epilepsy, Tonic-Clonic; Female; Fluoxetine; Humans; Psychotic Disorders; | 1993 |
Psychopharmacotherapy of psychiatric syndromes in asymptomatic and symptomatic HIV infection.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antidepressive Agents; Anxiety Disorders; Bupropion; Depr | 1991 |
9 trials available for fluoxetine and Psychoses
| Article | Year |
|---|---|
A Sequential Adaptive Intervention Strategy Targeting Remission and Functional Recovery in Young People at Ultrahigh Risk of Psychosis: The Staged Treatment in Early Psychosis (STEP) Sequential Multiple Assignment Randomized Trial.
Topics: Adolescent; Antipsychotic Agents; Female; Fluoxetine; Humans; Psychotic Disorders; Quality of Life; | 2023 |
The response of psychotic-like symptoms to fluoxetine monotherapy in non-psychotic major depressive disorder.
Topics: Adolescent; Adult; Aged; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Dis | 2009 |
An open study of olanzapine and fluoxetine for psychotic major depressive disorder: interim analyses.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Depressive Disord | 2002 |
A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features.
Topics: Adult; Analysis of Variance; Benzodiazepines; Chi-Square Distribution; Depressive Disorder, Major; D | 2004 |
Serum concentrations of clozapine and its major metabolites: effects of cotreatment with fluoxetine or valproate.
Topics: Adult; Clozapine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Comb | 1994 |
Concentrations of the enantiomers of fluoxetine and norfluoxetine after multiple doses of fluoxetine in cytochrome P4502D6 poor and extensive metabolizers.
Topics: Adult; Antidepressive Agents, Second-Generation; Cytochrome P-450 CYP2D6; Dose-Response Relationship | 2001 |
Effect of fluoxetine and imipramine on the pharmacokinetics and tolerability of the antipsychotic quetiapine.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Antipsychotic Agents; Bipolar Disorder; | 2002 |
The effect of fluoxetine on the pharmacokinetics and safety of risperidone in psychotic patients.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Area Under | 2002 |
Addition of fluoxetine to treatment of schizophrenic patients.
Topics: Antipsychotic Agents; Drug Therapy, Combination; Fluoxetine; Humans; Male; Psychotic Disorders; Schi | 1991 |
26 other studies available for fluoxetine and Psychoses
| Article | Year |
|---|---|
Erotomania in Depressive Psychosis: Mood Incongruent Delusion in a Depressive Young Woman.
Topics: Bipolar Disorder; Delusions; Depression; Depressive Disorder; Emotions; Female; Fluoxetine; Humans; | 2019 |
Successful treatment of tuberous sclerosis with psychosis and obsessive-compulsive disorder: A case report.
Topics: Adult; Antipsychotic Agents; Fluoxetine; Humans; Male; Obsessive-Compulsive Disorder; Psychotic Diso | 2015 |
Sertindole and fluoxetine overdose with benign outcome.
Topics: Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Azabicyclo Compounds; Blood P | 2010 |
Association of DRD2 and ANKK1 polymorphisms with prolactin increase in olanzapine-treated women.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Drug Combinations; Female; Fluox | 2011 |
Association of DRD2 and ANKK1 polymorphisms with prolactin increase in olanzapine-treated women.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Drug Combinations; Female; Fluox | 2011 |
Association of DRD2 and ANKK1 polymorphisms with prolactin increase in olanzapine-treated women.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Drug Combinations; Female; Fluox | 2011 |
Association of DRD2 and ANKK1 polymorphisms with prolactin increase in olanzapine-treated women.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Drug Combinations; Female; Fluox | 2011 |
Association of DRD2 and ANKK1 polymorphisms with prolactin increase in olanzapine-treated women.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Drug Combinations; Female; Fluox | 2011 |
Association of DRD2 and ANKK1 polymorphisms with prolactin increase in olanzapine-treated women.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Drug Combinations; Female; Fluox | 2011 |
Association of DRD2 and ANKK1 polymorphisms with prolactin increase in olanzapine-treated women.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Drug Combinations; Female; Fluox | 2011 |
Association of DRD2 and ANKK1 polymorphisms with prolactin increase in olanzapine-treated women.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Drug Combinations; Female; Fluox | 2011 |
Association of DRD2 and ANKK1 polymorphisms with prolactin increase in olanzapine-treated women.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Drug Combinations; Female; Fluox | 2011 |
Association of DRD2 and ANKK1 polymorphisms with prolactin increase in olanzapine-treated women.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Drug Combinations; Female; Fluox | 2011 |
Association of DRD2 and ANKK1 polymorphisms with prolactin increase in olanzapine-treated women.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Drug Combinations; Female; Fluox | 2011 |
Association of DRD2 and ANKK1 polymorphisms with prolactin increase in olanzapine-treated women.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Drug Combinations; Female; Fluox | 2011 |
Association of DRD2 and ANKK1 polymorphisms with prolactin increase in olanzapine-treated women.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Drug Combinations; Female; Fluox | 2011 |
Association of DRD2 and ANKK1 polymorphisms with prolactin increase in olanzapine-treated women.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Drug Combinations; Female; Fluox | 2011 |
Association of DRD2 and ANKK1 polymorphisms with prolactin increase in olanzapine-treated women.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Drug Combinations; Female; Fluox | 2011 |
Association of DRD2 and ANKK1 polymorphisms with prolactin increase in olanzapine-treated women.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Drug Combinations; Female; Fluox | 2011 |
Association of DRD2 and ANKK1 polymorphisms with prolactin increase in olanzapine-treated women.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Drug Combinations; Female; Fluox | 2011 |
Association of DRD2 and ANKK1 polymorphisms with prolactin increase in olanzapine-treated women.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Drug Combinations; Female; Fluox | 2011 |
Association of DRD2 and ANKK1 polymorphisms with prolactin increase in olanzapine-treated women.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Drug Combinations; Female; Fluox | 2011 |
Association of DRD2 and ANKK1 polymorphisms with prolactin increase in olanzapine-treated women.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Drug Combinations; Female; Fluox | 2011 |
Association of DRD2 and ANKK1 polymorphisms with prolactin increase in olanzapine-treated women.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Drug Combinations; Female; Fluox | 2011 |
Association of DRD2 and ANKK1 polymorphisms with prolactin increase in olanzapine-treated women.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Drug Combinations; Female; Fluox | 2011 |
Association of DRD2 and ANKK1 polymorphisms with prolactin increase in olanzapine-treated women.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Drug Combinations; Female; Fluox | 2011 |
Association of DRD2 and ANKK1 polymorphisms with prolactin increase in olanzapine-treated women.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Drug Combinations; Female; Fluox | 2011 |
Association of DRD2 and ANKK1 polymorphisms with prolactin increase in olanzapine-treated women.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Drug Combinations; Female; Fluox | 2011 |
Aripiprazole associated with acute dystonia, akathisia, and parkinsonism in a single patient.
Topics: Adult; Akathisia, Drug-Induced; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Arip | 2012 |
[To enhance the study of the diagnosis and treatment of psychoses during pregnancy and postpartum stage].
Topics: Antidepressive Agents, Second-Generation; Female; Fluoxetine; Humans; Postpartum Period; Pregnancy; | 2003 |
QTc prolongation in multiple drug overdose.
Topics: Adult; Bupropion; Drug Overdose; Fluoxetine; Humans; Long QT Syndrome; Male; Piperazines; Psychotic | 2004 |
Sertraline and fluoxetine: safe treatments for children and adolescents with epilepsy and depression.
Topics: Adolescent; Child; Child, Preschool; Depression; Epilepsy; Female; Fluoxetine; Humans; Male; Neurolo | 2007 |
Acute myocarditis associated with clozapine.
Topics: Acute Disease; Adult; Antidepressive Agents; Antipsychotic Agents; Clozapine; Drug Interactions; Dru | 2007 |
Water, water, everywhere, nor any drop to drink: climate change delusion.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Benzodiazepines; Climate | 2008 |
Fluoxetine for the prolonged treatment of schizophreniform psychosis.
Topics: Adult; Drug Therapy, Combination; Female; Fluoxetine; Humans; Long-Term Care; Male; Psychotic Disord | 1995 |
Antidepressant-associated mania: a controlled comparison with spontaneous mania.
Topics: Adult; Akathisia, Drug-Induced; Antidepressive Agents; Antidepressive Agents, Tricyclic; Bipolar Dis | 1994 |
Managing psychotic symptoms when the diagnosis is unclear.
Topics: Adult; Diagnosis, Differential; Fluoxetine; Fluphenazine; Humans; Male; Obsessive-Compulsive Disorde | 1993 |
Postpartum obsessive compulsive disorder: a case series.
Topics: Adult; Clomipramine; Desipramine; Diagnosis, Differential; Female; Fluoxetine; Follow-Up Studies; Hu | 1993 |
Adverse events and tolerability of the combination of fluoxetine/lithium compared with fluoxetine.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Antidepressive Agents, Seco | 1996 |
Lactation associated with fluoxetine treatment.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Depressive Disorder; Dru | 1995 |
Ritanserin as adjunct to fluoxetine treatment of OCD patients with psychotic features.
Topics: Adult; Antidepressive Agents, Second-Generation; Drug Therapy, Combination; Female; Fluoxetine; Huma | 1997 |
Gynecomastia with risperidone-fluoxetine combination.
Topics: Adult; Antipsychotic Agents; Drug Combinations; Fluoxetine; Gynecomastia; Humans; Male; Psychiatric | 1999 |
Quetiapine resolves psychotic depression in an adolescent boy.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Depressive Disorder; Dib | 2001 |
Ethics, humility, and psychotropic medications.
Topics: Adult; Attitude of Health Personnel; Dose-Response Relationship, Drug; Ethics, Medical; Female; Fluo | 2001 |
Loxapine and schizoaffective disorders.
Topics: Adult; Drug Therapy, Combination; Drug Tolerance; Female; Fluoxetine; Follow-Up Studies; Humans; Lox | 1991 |
Fluoxetine and parkinsonism in patients taking carbamazepine.
Topics: Aged; Bipolar Disorder; Carbamazepine; Drug Interactions; Drug Therapy, Combination; Female; Fluoxet | 1991 |
Treatment of psychotic symptoms in OCD patients.
Topics: Antipsychotic Agents; Catatonia; Drug Therapy, Combination; Female; Fluoxetine; Humans; Middle Aged; | 1990 |
Elevation of plasma concentrations of haloperidol after the addition of fluoxetine.
Topics: Adult; Aged; Basal Ganglia Diseases; Drug Interactions; Drug Therapy, Combination; Female; Fluoxetin | 1991 |
Detection of psychoactive drugs in vivo in humans using 19F NMR spectroscopy.
Topics: Brain; Depressive Disorder; Fluoxetine; Humans; Magnetic Resonance Spectroscopy; Models, Anatomic; M | 1991 |
Fluoxetine and neuroleptic malignant syndrome.
Topics: Depressive Disorder; Drug Therapy, Combination; Fluoxetine; Humans; Male; Middle Aged; Neuroleptic M | 1990 |